parkinson disease second common neurodegen world betaarrestin report import protein involve dopamine receptor desensit essential more potent value pharmacology inactive g proteincoupl kind arresting treatment patient recent shown studi interact regal chemin compound use capillary zone electrophoresis result screen reveal three remark inhibit betaarrestind among promise therapy method use studi great applied largescal drug value 